Hims & Hers to offer compounded peptides
The Hill · August 11, 2026Original source ↗
What happened
Hims & Hers Health announced plans to sell compounded peptides during a recent earnings call. CEO Andrew Dudum stated that the company is developing a high-quality peptides experience, including U.S. manufactured products, clinical guidance, and blood testing.
Why it matters
This development could provide consumers with new options for peptide treatments.
How this story affects people
How does this story affect you if you are interested in peptide treatments?
This announcement may provide you with new options for accessing peptide therapies. The company's focus on U.S. manufacturing and clinical guidance could enhance the quality and safety of these treatments.
Want this written about you?
The breakdown above is the shared version, for kinds of people. In the app, Ripple uses your job, your city, and your family, then writes that part about you.
Get your RippleMore stories
- HealthEbola outbreak in Democratic Republic of Congo sees significant rise in cases and deaths
- HealthTrump proposes splitting combination vaccines into separate injections
- HealthEbola outbreak in DRC spreads to sixth province
- HealthSurrogate gives birth in Texas to baby with heart defect after fleeing from California